trending Market Intelligence /marketintelligence/en/news-insights/trending/tbihgfsm08hmapujy444wa2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Antibe, Kwang Dong Pharmaceutical partner to develop anti-inflammatory drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Antibe, Kwang Dong Pharmaceutical partner to develop anti-inflammatory drug

Antibe Therapeutics Inc. and Kwang Dong Pharmaceutical Co. Ltd. signed a licensing deal to develop and commercialize anti-inflammatory drug ATB-346 in South Korea.

Under the agreement, Antibe will get C$13 million in development and commercial milestone payments, including C$1.3 million in up-front payment. The company will also receive a double-digit royalty on the South Korean net sales of the medicine, once commercialized.

ATB-346 is an anti-inflammatory drug being developed by Antibe to prevent ulcers and bleeding in the gastrointestinal tract due to non-steroidal anti-inflammatory drugs. The company has completed a phase 2b gastrointestinal safety study of the drug, in which ATB-346 was shown to be safer for the gastrointestinal tract than naproxen, a nonsteroidal anti-inflammatory drug that is widely used for treating pain but is associated with causing gastrointestinal ulceration and bleeding.

The Toronto-based company intends to begin a phase 2b dose-ranging efficacy study of the drug in September.

MedCI LLC acted as adviser on the transaction.